• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Evolent signs agreement to acquire artificial intelligence utilization management products and team from Machinify

    6/4/24 7:00:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary
    Get the next $EVH alert in real time by email
    • Machinify solution seeks to accelerate the efficiency, quality, and clinical value of Evolent's specialty condition management platform through AI-enabled clinical workflow automation
    • Machinify technology leverages the latest advances in applied machine learning, large language models and data analytics
    • Acquisition expected to benefit health plans, clinicians, and members

    WASHINGTON, June 4, 2024 /PRNewswire/ -- Evolent Health, Inc. ("Evolent" or "the Company"), (NYSE:EVH) a company focused on achieving better health outcomes for people with complex conditions, today announced it has entered into an agreement to acquire certain assets of Machinify and the exclusive, perpetual and royalty-free license of Machinify Auth, a proven software platform that leverages the latest advances in artificial intelligence to increase the clinical quality, speed and consistency of the clinical reviews for all specialty conditions. Evolent plans to integrate the Machinify Auth team, software applications and AI capabilities into its leading platform. Evolent and Machinify will also enter into a multi-year services agreement to support the success of the acquisition. Evolent believes the acquisition will add significant value for Machinify and Evolent's health plans, providers and members. The acquisition is subject to customary closing conditions.

    Evolent believes the addition of scalable AI technology will enable the Company to leapfrog standard industry processes by increasing the number of first-pass approvals as well as streamlining manual data collection and analysis associated with complex medical decision making. Such manual transactions can be time intensive and require clinical staff to read, search, identify, and synthesize key data from extensive medical record histories during case reviews. The solution to be acquired, Machinify Auth, functions as a co-pilot for nurses and doctors and brings a proven track record of reducing clinician workforce time by an average of 55% for complex, manual reviews for a large national payer customer and its provider network. With this capability, Evolent clinicians will be able to spend more time guiding providers to higher-value choices, strengthening the Company's core value proposition of higher quality outcomes and cost savings, while also reducing administrative burden for providers and members.

    "The acquisition of Machinify Auth will create an incredibly powerful opportunity for Evolent and for our client base of approximately 70 health plans," stated Seth Blackley, Co-Founder and Chief Executive Officer of Evolent. "Machinify has built a proven AI business that currently reviews over $200 billion in medical claims annually. The acquired assets consist of developers and proprietary, scalable software code as well as existing client relationships that fit with our product strategy at Evolent. Further, we believe by embedding Machinify technology into our platform and wrapping it with broader condition management services we can unlock additional value for health plans, providers, and members. Finally, this solution will allow Evolent, on a SaaS basis initially, to support value-based condition management and provider engagement across all specialties, not just for our three focus areas of oncology, cardiology and musculoskeletal care."

    "We founded Machinify to bring innovation to health care and to leverage healthcare data at scale to drive down costs and improve outcomes," said Prasanna Ganesan, Founder and Chief Executive Officer of Machinify. "Evolent shares our vision for fundamental process transformation through the use of advanced technology. We are excited to partner with them to pair Machinify's pioneering AI platform with Evolent's considerable industry-leading solutions and footprint across the payer landscape."

    Machinify is a privately held company based in Palo Alto, California. Upon closing, Evolent will be acquiring certain assets and the exclusive license to the Machinify Auth platform. In addition, certain employees of Machinify will be re-badged as Evolent employees upon closing. Lastly, Machinify and Evolent expect to enter into a long-term services agreement at closing to support the development and integration of the platform with Evolent. The acquisition is immaterial to Evolent's revenue outlook and is estimated to be neutral to Adjusted EBITDA in the first year after closing. This transaction is anticipated to close in the third quarter of 2024.

    Evolent Health Logo (PRNewsfoto/Evolent Health)

    About Evolent

    Evolent (NYSE:EVH) specializes in better health outcomes for people with complex conditions through proven solutions that make healthcare simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in healthcare nationally. Learn more about how Evolent is changing the way healthcare is delivered by visiting evolent.com.

    About Machinify

    Machinify is transforming healthcare administration with AI. The company serves payers of all sizes with over 50 million active lives today. The company is headquartered in Palo Alto and is backed by Battery Ventures, Matrix Partners, and GV. Go to www.machinify.com to learn more about how Machinify is transforming healthcare administration with AI.

    Investors: Seth R. Frank, [email protected]

    Media
    : Jamie Manfuso, [email protected]

    Forward-Looking Statements - Cautionary Language

    Certain statements made in this release and in other written or oral statements made by us or on our behalf are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). A forward-looking statement is a statement that is not a historical fact and, without limitation, includes any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like: "believe," "anticipate," "expect," "estimate," "aim," "predict," "potential," "continue," "plan," "project," "will," "should," "shall," "may," "might" and other words or phrases with similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to future actions, our business outlook and future performance, including our ability to integrate Machinify into our operations, the expected benefits of the Machinify acquisition, and the expected timing for the closing of the Machinify acquisition. We claim the protection afforded by the safe harbor for forward-looking statements provided by the PSLRA. These statements are only predictions based on our current expectations and projections about future events. Forward-looking statements involve risks and uncertainties that may cause actual results, level of activity, performance or achievements to differ materially from the results contained in the forward-looking statements. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Our Annual Report on Form 10-K for the year ended December 31, 2023, and other documents filed with the SEC include risk factors that could affect our businesses and financial performance. Moreover, we operate in a rapidly changing and competitive environment. New risk factors emerge from time to time, and it is not possible for management to predict all such risk factors. Further, it is not possible to assess the effect of all risk factors on our businesses or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. In addition, we disclaim any obligation to update any forward-looking statements to reflect events or circumstances that occur after the date of this release.

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/evolent-signs-agreement-to-acquire-artificial-intelligence-utilization-management-products-and-team-from-machinify-302162679.html

    SOURCE Evolent Health

    Get the next $EVH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EVH

    DatePrice TargetRatingAnalyst
    11/13/2025$7.00Equal-Weight → Overweight
    Stephens
    11/13/2025$7.00Outperform
    BMO Capital Markets
    1/10/2025$15.00Buy
    Needham
    12/3/2024$36.00 → $29.00Buy
    BTIG Research
    11/8/2024$38.00 → $16.00Overweight → Equal-Weight
    Stephens
    10/11/2024$35.00Overweight
    KeyBanc Capital Markets
    8/9/2024$28.00 → $33.00Hold → Buy
    Truist
    4/22/2024$40.00Buy
    Citigroup
    More analyst ratings

    $EVH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evolent Health upgraded by Stephens with a new price target

    Stephens upgraded Evolent Health from Equal-Weight to Overweight and set a new price target of $7.00

    11/13/25 9:38:39 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    BMO Capital Markets initiated coverage on Evolent Health with a new price target

    BMO Capital Markets initiated coverage of Evolent Health with a rating of Outperform and set a new price target of $7.00

    11/13/25 9:13:18 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Needham initiated coverage on Evolent Health with a new price target

    Needham initiated coverage of Evolent Health with a rating of Buy and set a new price target of $15.00

    1/10/25 7:49:47 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Springstubb Brendan B bought $38,199 worth of shares (10,000 units at $3.82), increasing direct ownership by 20% to 58,821 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    11/19/25 4:23:02 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Director Holder Diane bought $25,518 worth of shares (2,735 units at $9.33), increasing direct ownership by 4% to 70,584 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/10/25 8:20:54 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    PRESIDENT Mccarthy Daniel Joseph bought $99,470 worth of shares (11,040 units at $9.01), increasing direct ownership by 3% to 389,004 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/10/25 8:18:12 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Smith Jill D. was granted 23,137 shares (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    1/6/26 4:10:35 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Chief Financial Officer Ramos Mario was granted 587,500 shares (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    1/5/26 4:13:26 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    New insider Ramos Mario claimed no ownership of stock in the company (SEC Form 3)

    3 - Evolent Health, Inc. (0001628908) (Issuer)

    1/5/26 4:10:53 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evolent To Release 2025 Fourth Quarter and Year-End Financial Results on Tuesday, February 24, 2026

    WASHINGTON, Feb. 4, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its 2025 fourth quarter and year-end financial results on Tuesday, February 24, 2026, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evolent call" 15 minutes prior to th

    2/4/26 11:02:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent Reports Inducement Award Under NYSE Listing Rule 303A.08

    WASHINGTON, Jan. 2, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, announced that the Compensation Committee of Evolent's Board of Directors approved the grant of a one-time time-based restricted stock unit award covering 587,500 shares of Evolent Class A common stock, par value $0.01 per share (the "Inducement Award"), to Mr. Mario Ramos ("Mr. Ramos"), Evolent's new Chief Financial Officer effective as of January 2, 2026. The Inducement Award was granted as an inducement material to Mr. Ramos e

    1/2/26 4:15:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent and American Oncology Network unveil innovative model seeking to improve cancer care while eliminating prior authorization burden

    WASHINGTON, Nov. 6, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, and American Oncology Network (AON), one of the nation's fastest-growing community oncology networks, today announced a new model enabling high-quality, more affordable, and connected cancer care — all without relying on prior authorization. The national partnership seeks to improve clinical decision-making by introducing quality-focused interventions, driving clinical insights through an innovative data and analytics platform, and rewarding providers for high-quality care. As providers demonstrate adherence to quality, they will

    11/6/25 4:12:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    Leadership Updates

    Live Leadership Updates

    View All

    Privia Health Expands Value-Based Care Footprint with Acquisition of Accountable Care Organization Business from Evolent Health

    ARLINGTON, Va., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced that it signed a definitive agreement to acquire an Accountable Care Organization (ACO) business from Evolent Health, Inc. (NYSE:EVH). The ACO business cares for over 120,000 attributed lives through the Medicare Shared Savings Program (MSSP), as well as various commercial and Medicare Advantage programs. With this transaction, Privia Health will now serve approximately 1.5 million attributed lives in value-based care (VBC) arrangements across commercial, Medicare, Medicare Advantage and Medicaid. Privia Health will pay $100 million in cash at closing and up to an additional $13 million su

    9/23/25 4:10:00 PM ET
    $EVH
    $PRVA
    Other Consumer Services
    Consumer Discretionary
    Medical/Nursing Services
    Health Care

    Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership

    Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to Succeed Greg Garrison as Chairman Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Go

    3/18/25 4:47:00 PM ET
    $CMBM
    $DOMO
    $EVH
    Radio And Television Broadcasting And Communications Equipment
    Technology
    Computer Software: Prepackaged Software
    Other Consumer Services

    Define Ventures Appoints Carolyn Magill as Venture Partner

    The former Aetion and Remedy Partners CEO joins Define to further drive innovation across provider, payer, and pharmaceutical sectors SAN FRANCISCO, March 11, 2025 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Carolyn Magill, former CEO of Aetion, has joined the firm as venture partner. Magill, leveraging her 25 years of invaluable experience scaling companies and fostering innovation within payer, provider, and pharmaceutical organizations, will partner with Define founders to scale their companies and become category-defining companies.

    3/11/25 5:30:00 AM ET
    $EVH
    $HIMS
    $LVGO
    Other Consumer Services
    Consumer Discretionary
    Medical/Nursing Services
    Health Care

    $EVH
    Financials

    Live finance-specific insights

    View All

    Evolent To Release 2025 Fourth Quarter and Year-End Financial Results on Tuesday, February 24, 2026

    WASHINGTON, Feb. 4, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its 2025 fourth quarter and year-end financial results on Tuesday, February 24, 2026, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evolent call" 15 minutes prior to th

    2/4/26 11:02:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent Announces Third Quarter 2025 Results

    Q3 2025 financial results ahead of expectations.Announces more than $500 million in newly-contracted annualized revenue to launch in 2026.Expands leadership team to support accelerating growth.WASHINGTON, Nov. 6, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended September 30, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "We are happy to deliver a strong quarter, in the top half of our guidance for both Ad

    11/6/25 4:10:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent To Release Third Quarter 2025 Financial Results on Thursday, November 6, 2025

    Company to Participate in Upcoming Conferences WASHINGTON, Oct. 9, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its third quarter 2025 financial results on Thursday, November 6, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evo

    10/9/25 8:30:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

    SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    11/12/24 9:55:15 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

    SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    8/7/24 7:47:40 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

    SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    7/10/24 10:10:34 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Evolent Health Inc

    SCHEDULE 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    2/13/26 1:22:30 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by Evolent Health Inc

    SCHEDULE 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    2/11/26 1:30:10 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by Evolent Health Inc

    SCHEDULE 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    2/5/26 1:23:13 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary